SLC25A3 and chronic myelogenous leukemia, BCR-ABL1 positive: SLC25A3 is involved in the discrimination of chronic phase from blast crisis chronic myeloid leukemia and therefore may help determine risk-based treatment strategies at diagnosis [28].